Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 10Colorectal Neoplasms 3HER2-positive Gastric Cancer 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2 1Gastric Adenocarcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × disitamab vedotin × Gastrointestinal × Clear all
NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡